The plasma clearance of pancuronium in patients with extrahepatic cholestasis was 16% lower than in a control group (1.47 ±0.11 mlmin"'kg" ' v. 1.76±0.21 mlmin"'kg"'), but the difference was not significant. A significant increase in the elimination half-life T± of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment ( V 2 ) was found in patients with extrahepatic cholestasis when compared with control patients. There was a significantly lower cumulative biliary excretion of pancuronium (0.3±0.3% v. 10.9±3.2% in the controls) during the 48-h period of observation. The biotransformation and cumulative urinary excretion patterns of pancuronium revealed no significant differences between the two groups of patients. The increase of 7* + pancuronium in patients with extrahepatic cholestasis was mainly a consequence of the increase in the volume of distribution. No significant differences in the plasma clearance, 7*/ or in the volume of distribution were observed with gallnminr in the patients with extrahepatic cholestasis when compared with the control group. The cumulative urinary excretion of gallamine during 48 h in both groups of patients was approximately 100%. We concluded that in patients with cholestasis and normal glomerular nitration, gallamine is probably more reliable than pancuronium for neuromuscular blockade.
Evidence of a decrease in the plasma clearance of pancuronium and the related compound Org 6368 and a prolongation of neuromuscular blockade has been obtained in cats with extrahepatic cholestasis. Gallamine, which is eliminated mainly by the renal route, had normal kinetics (Westra et al., 1980a) . Although pancuronium is excreted mainly in the urine in man (Agoston et al., 1973; Buzello, 1975) , a two-fold prolongation of the mean elimination half-life was found by Somogyi, Shanks and Triggs (1977) in patients with extrahepatic cholestasis. Animal studies have shown that inhibition of the hepatic uptake of pancuronium and Org 6368 in extrahepatic cholestasis might explain this pharmacological behaviour (Westra et al., 1980a) . In addition, the infusion of bile salts augmented the action of pancuronium, Org NC 45, Org 6368 and hexafiuorenium in cats, and this could be explained also by inhibition of the hepatic uptake of these agents (Vonk et al., 1979; Westra et al., 1980b) . The action of gallamine was not influenced significantly by bile salts (Vonk et al., 1979; Westra et al., 1980b) . The aim of this study was to establish whether the changes in pharmacokinetics and pharmacodynamics produced by extrahepatic cholestasis could be detected also in clinical practice. In addition, the appropriateness of a particular neuromuscular blocker for use in patients with jaundice was considered.
PATIENTS AND METHODS

Patients
Eleven patients with extrahepatic cholestasis undergoing surgery for the relief of obstruction of the bile duct, caused by either carcinoma or stones in the common bile duct, were studied. The characteristics of the patients and the diagnoses are listed in table I.
Routine indices of liver and renal function were determined and the concentration of the total bile salts in the plasma was measured using an enzymatic kit for spectrofluorimetric determination (Sterognost Flu, Nyegaard & Co., Oslo, Norway) . These patients were compared with a group of 17 patients who underwent cholecystectomy with or without choledochotomy, with insertion of a tightly-fitting end-drain in the common bile duct. Twelve of these patients received pancuronium (described in a previous report (Agoston et al., 1973) ) and five received gallamine.
Anaesthesia
Premedication consisted of atropine 0.5 mg and diazepam 10 mg i.m., approximately 30 min before the induction of anaesthesia. Anaesthesia was induced with thiopentone 125-250mg i.v. and maintained with a 33% oxygen in nitrous oxide mixture delivered by an Engstrom ventilator. E.c.g. and peripheral pulse wave were monitored. Suxamethonium 50-100mg was given i.v. to facilitate tracheal intubation. Occasional doses of fentanyl 20-50 jig, were administered i.v. during the operation with or without droperidol 2.5-10mg i.v.
After recovery from the neuromuscular blockade produced by suxamethonium, a single dose of gallamine 2.5mgkg~ ' was injected i.v. over 30s (n = 4; nos 1-4) or a rapid single dose of pancuronium 6mg was given i.v. (n -7; nos 5-11).
During surgery the patients received an infusion of 2.5% glucose in 0.45% saline, plasma or whole blood as appropriate. The duration of the operations varied from 90 to 150 min.
Experimental and analytical procedure
Venous blood samples (6 ml) were removed at 2, 5, 10, 20, 30, 60, 90, 120, 240, 360 and 480 min after the administration of pancuronium or gallamine. The blood was allowed to clot; after centrifugation the serum was separated and kept at -30 C until chemical analysis could be performed. Urine (voided spontaneously or from a bladder catheter) was collected for 48 h after administration of the neuromuscular blockers.
Bile samples were obtained from patients with a drain in the bile duct at 12-h intervals for at least 48 h. Urine and bile were deep frozen for later analysis.
The spectrofluorimetric determination of pancuronium and gallamine and thin-layer chromatography of these bis(tris)-quaternary ammonium compounds and metabolites have been described in detail elsewhere (Kersten, Meijer and Agoston, 1973; Agoston et al., 1978) . The fiuorimetric method for bisquaternary ammonium compounds does not discriminate between pancuronium and its deacetylated metabolite(s). Chromatographic quantification of the bisquaternary ammonium compounds in urine as described previously (Kersten, Meijer and Agoston, 1973) was improved by using a mixture of isopropanol-Nal 100ml (7.5 g) for development of the plates.
Pharmacokinetic calculations
The individual plasma decay curves of pancuronium and gallamine were fitted with a leastsquare regression program, according to two-and three-compartment open models. Fitting of the experimental data according to these models was compared statistically at a 95% significance level (Boxenbaum, Riegelman and Elashoff, 1974) . In all patients (pancuronium and gallamine), since a three-compartment model did not give a significantly better fit than a two-compartment model, a two-compartment open model was used.
Pharmacodynamic calculations
To obtain an impression of the consequences of pharmacokinetics for the neuromuscular blockade of pancuronium we calculated expected duration of action. Data on the neuromuscular blockade of pancuronium in man were taken from a previous report (Agoston et al., 1977) , in which the relationship between the plasma concentrations of pancuronium and its neuromuscular blocking effect, in subjects undergoing general anaesthesia for surgical operations, was determined. In this particular study the response of the adductor pollicis muscle of the thumb to supramaximal stimulation of the ulnar nerve was used as a measure of neuromuscular blockade. The plasma concentrations of pancuronium at the start of recovery, 25%, 50% and 75% recovery of neuromuscular blockade were reported to be 0.21, 0.13, 0.11 and 0.10 ug ml" 1 respectively. Interpolation of these values by computer-fitting into the mean plasma disappearance curves, using the mean intercept and half-life data of the regression lines obtained by balanced iterative peeling of the curves, was performed for both groups of patients receiving pancuronium. It was assumed that the plasma concentrations of pancuronium determine the degree of neuromuscular blockade and that cholestasis does not influence significantly the relation of plasma concentration and effect, as found by Somogyi, Shanks and Triggs (1977) for this type of patient.
Statistics
All values are given as mean +SEM. Statistical significance was tested using Wilcoxon's test for unpaired data with a 95% significance level.
RESULTS
Clinical chemistry
No impairment of the glomerular filtration could be observed in the patients with extrahepatic cholestasis as shown by normal plasma concentrations of creatinine and urea (except for patient no. 8).
Liver functions tests revealed significant increases in the concentrations of alkaline phosphatase (AP), lactate dehydrogenase (LDH), glutamic-pyruvic transaminase (GPT) and glutamic-oxaloacetic transaminase (GOT) in the patients with extrahepatic cholestasis. A slight increase in total cholesterol concentration and a significant increase in plasma concentration of bilirubin were detected. Approximately 70% of the total bilirubin in the plasma was present as a glucuronide conjugate.
Total bile salt concentrations in plasma during extrahepatic cholestasis, were increased approximately 40-fold compared with controls ( fig. 1) . Relief of the biliary obstruction caused a linear decay of the plasma bile salt concentration (approximately 30% decrease during the first 8 h). The degree of cholestasis, as indicated by the values of the plasma concentrations of total bile salt and total bilirubin, did not differ statistically between the two groups of cholestatic patients (those receiving pancuronium and those receiving gallamine). All clinical chemistry data are listed in table II.
Pharmacokinetics of pancuronium
The pharmacokinetic parameters such as the half-lives (7y and T/), the plasma clearance (C/), the volume of central compartment (F,), the 
Pharmacokinetics of gallamine
The pharmacokinetics of gallamine did not show significant differences between patients with extrahepatic cholestasis and the controls (table  III) . The patterns of urinary excretion for gallamine in both groups of patients are shown in figure  2 . There is no evidence of any difference between the two groups. Total recovery from bile and urine of gallamine during 48 h approximated 100% in both groups (104.2% v. 98.4%; table IV).
Biotransformation of pancuronium
Thin-layer chromatography of urine and bile samples of both groups of patients receiving pancuronium was performed to obtain information on the biotransformation of the drug in extrahepatic cholestasis. These investigations revealed that, in patients with extrahepatic cholestasis, pancuronium is metabolized to its 3-hydroxy derivative to about the same extent as in the control group of patients (18.1% v. 25.8% of the dose respectively; table IV).
Pharmacodynamics of pancuromum
Computer-simulation with the data on pharmacokinetics and previously published data on the relation between plasma concentration and effect of pancuronium were performed. For the group of patients with extrahepatic cholestasis a mean duration to the start of recovery of neuromuscular blockade of 32 min was computed; this value was 56 min for the control group. The mean duration of action to 25, 50 and 75% recovery of neuromuscular blockade would be respectively 159, 212 and 246 min for the patients with extrahepatic cholestasis and 148, 182 and 201 min for the control patients. 
DISCUSSION
The pharmacokinetics of gallamine in patients with hepato-biliary disease did not differ significantly from the control group. No change in plasma clearance or volume of distribution was observed. Cumulative urinary excretion was similar to that in the control patients and amounted to approximately 100% within 48 h. Biliary excretion of gallamine in man is negligible, as in animals (Feldman, Cohen and Golling, 1969; Westra et al., 1980a) . Consequently, possible interactions between bile salts and gallamine will be unimportant quantitatively.
The most important changes in the pharmacokinetics of pancuronium in patients suffering from extrahepatic cholestasis were a significant increase in the elimination half-life (Tj) and a significant decrease of the biliary excretion of the drug. A prolongation of T^ can be caused either by a decrease in the plasma clearance or by an increase in the volume of distribution. Both parameters tended to change in our patients with extrahepatic cholestasis. However, since the decrease in the plasma clearance in the cholestatic patients was only moderate, if changed at all, we conclude that the 1.6-fold increase of T^ is mainly a consequence of the increase in the volume of distribution of pancuronium. No changes in urinary excretion or biotransformation of pancuronium were observed in patients with cholestasis compared with controls. Therefore, the trend to a decrease in plasma clearance may be attributed to decrease in the hepatic elimination of pancuronium in cholestasis. A study in the cat revealed that there was inhibition of hepatic uptake of Org 6368 and pancuronium in extrahepatic cholestasis most probably attributable to an increase in the plasma bile salt concentration (Westra et al., 1980a) . This was confirmed in cats in which a prolongation of the action of pancuronium, Org 6368, Org NC45 and hexafluorenium was obtained by the infusion of bile salt (Vonk et al., 1979; Westra et al., 1980b) . The plasma concentrations of the bile salts in the patients with extrahepatic cholestasis in the present study were similar to those found in cats with experimental cholestasis during 9-10 days (Westra et al., 1980a) . Thus, inhibition of hepatic elimination of drugs in hepato-biliary diseases might be a result of an interaction with bile salts, the concentration of which can increase readily under pathological conditions. Our pharmacokinetic data concerning the fate of pancuronium in patients with extrahepatic cholestasis are in contrast with a similar study of Somogyi, Shanks and Triggs (1977) in man in which Tj 270min, plasma clearance 0.97mlmin~ 'kg and V" 306.5 ml kg" 1 were reported. Tf was increased two-fold and the mean plasma clearance decreased by a factor of two compared with the control patients. The steady state volume of distribution did not differ significantly from the control value of 261.1 mlkg"
1 . It is known that the major component of the plasma clearance of pancuronium in man is represented by renal excretion (Agostonetal., 1973; Buzello, 1975) . It is generally accepted that the renal excretion of the polar, highly water-soluble non-depolarizing neuromuscular blockers occurs by glomerular filtration (Raaflaub and Frey, 1972; Cohen, Brewer and Smith, 1967) . Although Somogyi, Shanks and Triggs (1977) did not present data on renal function, the cumulative urinary excretion of pancuronium and its metabolites in cholestasis was normal and is in agreement with our data. Consequently, there is no reason to suppose that renal function was other than normal in their patients with cholestasis. Therefore, the relatively low plasma clearance of pancuronium of only 0.97mlmin~ "kg" ', reported by Somogyi, Shanks and Triggs (1977) in patients with cholestasis, compared with 1.86mlmin" ' kg" ' in the control patients (Somogyi, Shanks and Triggs, 1976) cannot be explained simply, even if we take age into account. It is possible that the lack of blood sampling in the very last part of the plasma disappearance curves may have led to inaccuracy in the calculations of the plasma clearance values.
A decrease in the plasma protein binding of drugs increases V". Enlargement of the volume of distribution as a result of decreased plasma protein binding has been reported for various drugs (Affrime and Reidenberg, 1975; Ghoneim and Pandya, 1975; Olsen, Bennett and Porter, 1975; Klotz, 1976) . In the group of patients with extrahepatic cholestasis, suffering mainly from neoplasia, we found markedly decreased plasma concentrations of total protein and albumin, respectively 58+2glitre" 1 and 28±lglitre" 1 v. 73 ± 2 g litre " ' and 43 +1 g litre " ' for the control group. A decrease in the plasma protein binding of drugs can be caused by a decrease in plasma protein concentrations or impairment of the binding, or both. Hooper and colleagues (1973) found that the decrease in plasma protein binding of phenytoin correlated significantly with the plasma bilirubin concentration. Albumin is quantitatively the most important plasma protein responsible for drug binding, but many drugs, especially basic drugs, may be bound to other plasma proteins as well (Ghoneim and Pandya, 1975) . The literature on the extent of plasma protein binding of pancuronium is conflicting; Waser (1973) , reported 20% binding for pancuronium in man and Thompson (1976) reported strong binding to gamma-globulin and moderate binding to albumin. Nevertheless, a decrease in plasma protein binding in patients with extrahepatic cholestasis may be one of the factors leading to the enlarged volume of distribution.
One of the most striking differences between our data and that of Duvaldestin and colleagues (1978) is that biotransformation of pancuronium in our patients with cholestasis was normal in contrast to their patients with cirrhosis, in whom the formation of the deacetylated 3-hydroxy metabolite was either non-existent or decreased markedly. Plasma cholinesterase, which is synthetized by the liver, may play a role in the breakdown of pancuronium (Kalow, 1959; Schuh, 1977) . Foldes and coworkers (1956) showed a marked decrease in the activity of this enzyme in patients with cirrhosis which resulted in a prolongation of the effect of suxamethonium. The normal concentration of the 3-hydroxy metabolite of pancuronium in our patients with extrahepatic cholestasis suggests that the concentration of plasma cholinesterase must be normal and this may imply that the impairment of hepatic elimination is not a direct result of parenchymal degeneration of the liver.
Computer simulation shows a tendency to prolongation of the neuromuscular blockade ( fig. 3 ) and is in agreement with the results of Somogyi, = control (n = 12); = cholestasis (« = 7). Shanks and Triggs (1977) , who found a 1.6-fold prolongation of action. However, as there was considerable individual variation, both normal and prolonged blockade can be expected with the use of pancuronium in this type of patient.
We conclude that, under pathological conditions involving increased plasma concentrations of bile salts and other cholephilic agents, neuromuscular blocking agents that are (partly) cleared from the plasma by the liver, may have an abnormal pattern of hepatic elimination which may lead to a prolonged duration of action. This phenomenon will be even more important for new neuromuscular blocking agents such as Org NC 45 for which hepatic elimination is probably more important (unpublished observations). We believe that the use of pancuronium in patients with hepato-biliary disease, such as cirrhosis and extrahepatic cholestasis, may produce several pitfalls in anaesthetic practice such as a prolonged duration of action, lack of appropriate effect after a single administration, but eventually a relative overdose after multiple administrations. In such patients gallamine is probably the most reliable drug for the production of neuromuscular blockade.
